BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation

CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)—- $BGNE #BGNE–BeiGene announces an sNDA for BRUKINSA in first-line chronic lymphocytic leukemia has been accepted in China with breakthrough therapy designation.
Click here to view original post